Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Riot Platforms Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Riot Platforms Inc trades at $14.62 (market cap $5.66B). The key difference: Riot Platforms Inc is far larger — about 2× Dyne Therapeutics Inc. Common Stock's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Riot Platforms Inc for 16 Days on average.
| DYN | RIOT | |
|---|---|---|
Market Cap | $2.81B | $5.66B |
Volume | 2,195,902 | 21,816,889 |
Sector | Health | Financials |
52-Week High | $26.78 | $28.67 |
52-Week Low | $14.60 | $11.83 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $2.13B | $6.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
RIOT Platforms trades at $16.67, up 1.21% with a bearish technical signal despite bullish oscillators. The company reported significant losses with a net income margin of -196.28% and negative cash flow from operations of -$573 million in 2025. Recent strategic shift to data center leasing secured $9.8 billion in contracted revenue through 2048, attracting major tenants like AMD.
Analyst consensus remains strongly bullish with 94.74% buy ratings and a $31.64 price target, suggesting substantial upside potential. Key risks include persistent negative profitability, high valuation multiples, and execution challenges in the AI infrastructure transition. The stock faces near-term pressure from consecutive earnings misses but offers long-term growth potential through its power capacity assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
